"Winter Disease and Summer Treatment" at that time
Release time:
2020-08-14
"Winter Disease and Summer Treatment" is in midsummer at the time of
. Many people are busy doing "three-volt moxibustion" to prepare for winter health care. Although the materials used in "Sanfu Moxibustion" are only ordinary ginger and moxa sticks, they are actually using summer, the most vigorous period of yang in nature, to allow the human body to replenish qi and warm yang, dispel cold and clear collaterals, thereby reducing deficiency and cold diseases. The probability of onset. This is "winter disease and summer treatment", a dialectical concept of traditional Chinese medicine, with the help of the trend of heaven and earth, to prevent seasonal diseases at the most economical cost.
The idea of "treating winter diseases in summer" can not only be used to regulate the body, but also for enterprise management. To put it another way, it is to think more about future difficulties when things are going well, to prevent possible falls during the rising period, to prepare for the upcoming "winter" in the prosperous "summer", to be prepared for danger in times of peace, and to take precautions.
Looking back on the development of the peak, it is undoubtedly the best period-operating income and profits are rising year by year, the stock price is strong against the market, and the first half of this year has created the best performance ever, which is gratifying enough. However, at the work analysis meeting in the first half of the year held not long ago, General Manager Yu Jianhong pointed out with great concern that most of the current benefit growth comes from the favorable market environment, and the endogenous growth capacity of enterprises is seriously insufficient. compared with the advanced enterprises of the same industry, there is an obvious gap in many aspects, and if the market situation is turbulent, it is likely to face a huge business crisis.
The general manager's analysis is by no means alarmist. The national economy and enterprise development have cyclical changes, and ups and downs are the real normal. For example, due to the promotion of "Belt and Road Initiative" and the increase of investment in infrastructure construction in Yunnan, the cement market is improving, and the peak benefit of Yunnan has doubled compared with the same period last year, but how many years can this benefit last? If you want to continue to "lead" after the foreseeable market decline in the future, you can only start from yourself, through technological transformation, management upgrades, and cost reduction, and enhance the comparative advantage with peers. Even so, whether you can achieve the current profit scale It is still unknown. Compared with the cement industry with strong regional effects, the medical and health industry has to face a multi-variety, multi-regional, and multi-standard market. The situation is more complicated. Once the environment changes, the pressure on enterprises can be imagined.
Innovation is the only way to enhance strength and lasting development. To this end, Chairman Jiang Xiaomeng proposed at the work analysis meeting in the first half of the year that efforts should be made to achieve the "five breakthroughs." the most fundamental thing is the breakthrough in people's thinking and concepts. Objectively speaking, the good operation of enterprises for many years has made many peak people complacent and slack off; others are only satisfied with their own year-on-year progress, but forget to look at the outside world more. The glittering report card has weakened our sense of crisis and slowed our progress. But the face is bright, if the lining can't keep up, when the "cold winter" comes, do we have enough "yang" to "keep out the cold"?
Recuperate your body as early as possible. The current peak has an incomparable good situation in the past. The internal capital, manpower and material resources are abundant, and the external policies and market are favorable, which give us the best time to adjust. At this time to seek "change", we can afford the cost, pay the time, even not afraid of trial and error, not afraid of detours. However, if we do this when we have to "change", it is more likely that we will fall into a deadlock that is difficult to take care of at the beginning and end, and we want to "change" but cannot. Therefore, taking advantage of this opportunity of "sufficient yang", our managers might as well take a serious look at themselves, come back to the enterprise version of "winter disease and summer treatment" in a down-to-earth manner, grasp the fundamentals to strengthen their health, and make themselves more powerful to resist the "cold winter" in the future ". (Hong Tao)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page